Our report suggests that CSF1R is a putative leukemogenic driver in some subsets of AMLs (Fig. 3 and Supplemental Fig. S8) and is thus targetable for the treatment of these AML patients, which is consistent with suggestions by others17. Here, CSF1R is linked to acute myeloid leukemia.